Citius Oncology shareholders approve doubling of stock incentive plan shares to 30M

CITIUS ONCOLOGY, INC.

At Oct 27 annual meeting, shareholders elected Class I directors Myron Holubiak and Joel Mayersohn for three-year terms.
Shareholders approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.
Ratification of Wolf & Company as independent auditor for fiscal year ending Sep 30, 2025 passed with 77.7M votes in favor.
Plan amendment doubles share pool for equity awards; approved by board Sep 19, 2025, now effective.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.